Impact of potential pregabalin or duloxetine drug–drug interactions on health care costs and utilization among Medicare members with fibromyalgia

References

• GoldenbergDLBradleyLAArnoldLMGlassJMClauwDJUnderstanding fibromyalgia and its related disordersPrim Care Companion J Clin Psychiatry200810213314418458727
   PubMedGoogle Scholar
• MeasePFibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatmentJ Rheumatol Suppl20057562116078356
   PubMedGoogle Scholar
• VincentALahrBDWolfeFPrevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology ProjectArthritis Care Res (Hoboken)201365578679223203795
   PubMed Web of Science ®Google Scholar
• AdamsEHDanielSChandranABA population-based survey and physician assessment of the characteristics and prevalence of fibromyalgiaPresented at the American College of Rheumatology Annual MeetingOctober 25–30, 2013San Diego, CA
   Google Scholar
• YunusMBInaniciFAldagJCMangoldRFFibromyalgia in men: comparison of clinical features with womenJ Rheumatol200027248549010685818
   PubMed Web of Science ®Google Scholar
• StaudRPharmacological treatment of fibromyalgia syndrome: new developmentsDrugs201070111420030422
   PubMed Web of Science ®Google Scholar
• WierwilleLFibromyalgia: diagnosing and managing a complex syndromeJ Am Acad Nurse Pract201224418419222486833
   PubMed Web of Science ®Google Scholar
• Arendt-NielsenLGraven-NielsenTCentral sensitization in fibromyalgia and other musculoskeletal disordersCurr Pain Headache Rep20037535536112946288
   PubMedGoogle Scholar
• YunusMBSymptoms and signs of fibromyalgia syndrome: an overviewWallaceDJCDFibromyalgia and Other Central Pain SyndromesPhiladelphia, PALippincott, Williams & Wilkins2005125132
   Google Scholar
• BennettRMClinical manifestations and diagnosis of fibromyalgiaRheum Dis Clin North Am200935221523219647138
   PubMed Web of Science ®Google Scholar
• WolfeFClauwDJFitzcharlesMAThe American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severityArthritis Care Res (Hoboken)201062560061020461783
   PubMed Web of Science ®Google Scholar
• WeirPTHarlanGANkoyFLThe incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codesJ Clin Rheumatol200612312412816755239
   PubMed Web of Science ®Google Scholar
• AbelesAMPillingerMHSolitarBMAbelesMNarrative review: the pathophysiology of fibromyalgiaAnn Intern Med20071461072673417502633
   PubMed Web of Science ®Google Scholar
• AbelesMSolitarBMPillingerMHAbelesAMUpdate on fibromyalgia therapyAm J Med2008121755556118589048
   PubMed Web of Science ®Google Scholar
• GoldenbergDLBurckhardtCCroffordLManagement of fibromyalgia syndromeJAMA2004292192388239515547167
   PubMed Web of Science ®Google Scholar
• CarvilleSFArendt-NielsenSBliddalHEULAREULAR evidence-based recommendations for the management of fibromyalgia syndromeAnn Rheum Dis200867453654117644548
   PubMed Web of Science ®Google Scholar
• FitzcharlesMASte-MariePAGoldenbergDLNational Fibromyalgia Guideline Advisory Panel2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summaryPain Res Manag201318311912623748251
   PubMed Web of Science ®Google Scholar
• SommerCHäuserWHAltenRDrug therapy of fibromyalgia syndrome. systematic review, meta-analysis and guidelineSchmerz2012263297310 German22760463
   PubMed Web of Science ®Google Scholar
• AblinJNAmitalHEhrenfeldMIsraeli Rheumatology AssociationGuidelines for the diagnosis and treatment of the fibromyalgia syndromeHarefuah201315212742747750751 Hebrew24483001
   PubMedGoogle Scholar
• PainterJTCroffordLJChronic opioid use in fibromyalgia syndrome: a clinical reviewJ Clin Rheumatol2013192727723364665
   PubMed Web of Science ®Google Scholar
• HäuserWPetzkeFSommerCComparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndromeJ Pain201011650552120418173
   PubMed Web of Science ®Google Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol19924566136191607900
   PubMed Web of Science ®Google Scholar
• KlabundeCNPotoskyALLeglerJMWarrenJLDevelopment of a comorbidity index using physician claims dataJ Clin Epidemiol200053121258126711146273
   PubMed Web of Science ®Google Scholar
• Von KorffMSaundersKThomasRGDe facto long-term opioid therapy for non-cancer painClin J Pain200824652152718574361
   PubMed Web of Science ®Google Scholar
• RosenbaumPRRubinDBThe central role of the propensity score in observational studies for causal effectsBiometrika19837014155
   Web of Science ®Google Scholar
• D’AgostinoRBPropensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStat Med19981719226522819802183
   PubMed Web of Science ®Google Scholar
• RosnerBFundamentals of BiostatisticsSeventh editionBoston, MABrooks/Cole Cengage Learning2010
   Google Scholar
• JonesAMRiceNBago d’UvaTBaliaSApplied Health EconomicsSecond editionNew York, NYRoutledge2013
   Google Scholar
• Lyrica (pregabalin) package insertNew YorkPfizer Inc2013
   Google Scholar
• Cymbalta (duloxetine) package insertIndianapolisEli Lilly and Company2012
   Google Scholar
• GoreMTaiKSChandranAZlatevaGLeslieDClinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual careJ Med Econ2012151193121970699
   PubMedGoogle Scholar
• KimSCLandonJESolomonDHClinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalinArthritis Care Res (Hoboken)201365111813181923861291
   PubMed Web of Science ®Google Scholar
• BurkeJPSanchezRJJoshiAVCappelleriJCKulakodluMHalpernRHealth care costs in patients with fibromyalgia on pregabalin vs duloxetinePain Pract2012121142221615857
   PubMed Web of Science ®Google Scholar
• PergolizziJVLabhsetwarSAPuenpatomRAJooSBen-JosephRHSummersKHPrevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioidsPain Pract201111323023920807350
   PubMed Web of Science ®Google Scholar
• PergolizziJVLabhsetwarSAPuenpatomRAJooSBen-JosephRSummersKHExposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptionsPain Pract201111432533621199317
   PubMed Web of Science ®Google Scholar
• JohnstonSSUdallMCappelleriJCCost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetineAm J Health Syst Pharm201370242207221724296843
   PubMed Web of Science ®Google Scholar
• SummersKHPuenpatomRARajanNBen-JosephROhsfeldtREconomic impact of potential drug-drug interactions in opioid analgesicsJ Med Econ201114439039621574905
   PubMedGoogle Scholar
• PergolizziJVLabhsetwarSAAmy PuenpatomRBen-JosephROhsfeldtRSummersKHEconomic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioidsPain Pract2012121455621923882
   PubMed Web of Science ®Google Scholar
• PergolizziJVLabhsetwarSAPuenpatomRABen-JosephROhsfeldtRSummersKHEconomic impact of potential drug-drug interactions among osteoarthritis patients taking opioidsPain Pract2012121334421951824
   PubMed Web of Science ®Google Scholar
• GoreMSadoskyATaiKSStaceyBA retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settingsClin Ther20072981655167017919547
   PubMed Web of Science ®Google Scholar
• GoreMTaiKSZlatevaGBala ChandranALeslieDClinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentinPain Pract201111652853921435162
   PubMed Web of Science ®Google Scholar
• WuNChenSYHallettLAOpioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs other therapiesPain Pract2011111485620602718
   PubMed Web of Science ®Google Scholar